Another next generation drug of IL-15 in preclinical trials is tumor-conditional IL-15 pro-cytokine (Pro-IL-15), designed by the team of Professor Fu Yangxin of Tsinghua University (Figure 2). Here, IL15 is linked to neoplasm.